Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. Donald Small

Donald Small, M.D., Ph.D.

Director, Division of Pediatric Oncology
Professor of Oncology


Appointment Phone


Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Division of Pediatric Oncology
  • Kyle Haydock Professor of Oncology
  • Professor of Oncology
  • Professor of Pediatrics

Centers & Institutes



The Johns Hopkins Hospital

Appointment Phone: 443-287-6997

600 N. Wolfe Street
Charlotte R. Bloomberg Childrens Center
Baltimore, MD 21287 map
Phone: 410-614-0994
Fax: 410-955-8897


Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia , Hodgkin's Disease , Leukemia, Medical Oncology, Myelodysplastic Syndromes (MDS), Non-Hodgkin's Lymphoma, Pediatric Oncology

Research Interests

Development of leukemia and lymphoma and FLT3 mutations.


Dr. Donald Small is Director of the Division of Pediatric Oncology and the Kyle Haydock Professor of Oncology. He holds joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He also directs the Johns Hopkins/National Cancer Institute Pediatric Hematology/Oncology Fellowship program.

Dr. Small’s laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. The investigations of FLT3 led Dr. Small and his team to discover drugs able to inhibit the cancer-generating activity of this important gene. His laboratory showed that a new class of drugs known as tyrosine kinase inhibitors could kill FLT3-affected cells, thus developing one of the earliest molecularly targeted cancer therapies. They then developed a test that enabled them to screen a host of additional kinase inhibitors and find several with great potency against FLT3. His group also led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how best to combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL.

Dr. Small’s lab continues to investigate leukemic processes and the role of stem cells in governing the activities of the FLT3 gene in leukemia. more

Featured Video

C-Answers - Pediatric and Childhood Cancer

    Additional Information

  • Education +


    • Johns Hopkins University School of Medicine / MD (1985)


    • Johns Hopkins University School of Medicine / Pediatrics (1987)


    • Johns Hopkins University School of Medicine (1990)
  • Research & Publications +

    Clinical Trial Keywords: FLT3 inhibitors, lymphoma, leukemia

    Selected Publications View all on PubMed

    Brown, P.; Levis, M.; McIntyre, E.; Griesemer, M.; Small, D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia. 2006 Aug;20(8):1368-1376.

    Kim, K.T.; Levis, M.; Small, D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol. 2006 Sep;134(5):500-509.

    Knapper, S.; Burnett, A.K.; Littlewood, T.; Kell, W.J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M.J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006 Nov 15;108(10):3262-3270.

    Levis, M.; Brown, P.; Smith, B.D.; Stine, A.; Pham, R.; Stone, R.; Deangelo, D.; Galinsky, I.; Giles, F.; Estey, E.; Kantarjian, H.; Cohen, P.; Wang, Y.; Roesel, J.; Karp, J.E.; Small, D. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-3483.

    Piloto, O.; Nguyen, B.; Huso, D.; Kim, K.T.; Li, Y.; Witte, L.; Hicklin, D.J.; Brown, P.; Small, D. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-4851.

    Radomska, H.S.; Basseres, D.S.; Zheng, R.; Zhang, P.; Dayaram, T.; Yamamoto, Y.; Sternberg, D.W.; Lokker, N.; Giese, N.A.; Bohlander, S.K.; Schnittger, S.; Delmotte, M.H.; Davis, R.J.; Small, D.; Hiddemann, W.; Gilliland, D.G.; Tenen, D.G. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006 Feb 20;203(2):371-381.

    Baldwin, B.R.; Li, L.; Tse, K.F.; Small, S.; Collector, M.; Whartenby, K.A.; Sharkis, S.J.; Racke, F.; Huso, D.; Small, D. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia. 2007 Apr;21(4):764-771.

    Brown, P.; McIntyre, E.; Rau, R.; Meshinchi, S.; Lacayo, N.; Dahl, G.; Alonzo, T.A.; Chang, M.; Arceci, R.J.; Small, D. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007 Aug 1;110(3):979-985.

    Kim, K.T.; Baird, K.; Davis, S.; Piloto, O.; Levis, M.; Li, L.; Chen, P.; Meltzer, P.; Small, D. Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol. 2007 Sep;138(5):603-615.

    Li, L.; Piloto, O.; Kim, K.T.; Ye, Z.; Nguyen, H.B.; Yu, X.; Levis, M.; Cheng, L.; Small, D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol. 2007 Apr;137(1):64-75.

    Piloto, O.; Wright, M.; Brown, P.; Kim, K.T.; Levis, M.; Small, D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007 Feb 15;109(4):1643-1652.

    Li, L.; Piloto, O.; Nguyen, H.B.; Greenberg, K.; Takamiya, K.; Racke, F.; Huso, D.; Small, D. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008 Apr 1;111(7):3849-3858.

    Sallmyr, A.; Fan, J.; Datta, K.; Kim, K.T.; Grosu, D.; Shapiro, P.; Small, D.; Rassool, F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage and misrepair: implications for poor prognosis in AML. Blood. 2008 Jan 11.

    Small, D. Targeting FLT3 for the treatment of leukemia. Seminars in hematology. 2008 Jul;45(3 Suppl 2):S17-21.

    Whartenby, K.A.; Small, D.; Calabresi, P.A. FLT3 inhibitors for the treatment of autoimmune disease. Expert Opin Investig Drugs. 2008 Nov;17(11):1685-1692.

    Pratz, K.W.; Cortes, J.; Roboz, G.J.; Rao, N.; Arowojolu, O.; Stine, A.; Shiotsu, Y.; Shudo, A.; Akinaga, S.; Small, D.; Karp, J.E.; Levis, M. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009 Apr 23;113(17):3938-3946.

    Schafer, E.; Irizarry, R.; Negi, S.; McIntyre, E.; Small, D.; Figueroa, M.E.; Melnick, A.; Brown, P. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010 Jun 10;115(23):4798-4809.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile